Atara Biotherapeutics (NASDAQ:ATRA) Raised to “Strong-Buy” at TD Cowen

Atara Biotherapeutics (NASDAQ:ATRA) was upgraded by equities researchers at TD Cowen to a “strong-buy” rating in a research note issued to investors on Friday,Zacks.com reports.

A number of other equities research analysts have also recently commented on the company. Canaccord Genuity Group increased their price target on Atara Biotherapeutics from $13.00 to $21.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. HC Wainwright reiterated a “neutral” rating on shares of Atara Biotherapeutics in a research note on Wednesday, August 21st. Finally, Mizuho raised shares of Atara Biotherapeutics from a “neutral” rating to an “outperform” rating and dropped their target price for the stock from $25.00 to $18.00 in a research report on Friday, August 16th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Atara Biotherapeutics has an average rating of “Moderate Buy” and an average price target of $16.67.

Atara Biotherapeutics Price Performance

NASDAQ ATRA opened at $12.18 on Friday. Atara Biotherapeutics has a 52 week low of $6.50 and a 52 week high of $39.50. The company has a 50 day moving average price of $9.63 and a 200 day moving average price of $10.02. The firm has a market cap of $70.13 million, a PE ratio of -0.47 and a beta of 0.50.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($2.93) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.77) by $0.84. The business had revenue of $40.19 million for the quarter, compared to analyst estimates of $23.00 million. During the same period in the previous year, the company posted ($16.50) earnings per share. On average, equities research analysts anticipate that Atara Biotherapeutics will post -12.12 earnings per share for the current fiscal year.

Institutional Trading of Atara Biotherapeutics

A number of hedge funds have recently modified their holdings of ATRA. Price T Rowe Associates Inc. MD lifted its holdings in Atara Biotherapeutics by 8,916.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 4,958,150 shares of the biotechnology company’s stock valued at $3,442,000 after acquiring an additional 4,903,159 shares during the period. Vestal Point Capital LP boosted its holdings in Atara Biotherapeutics by 11.3% in the 3rd quarter. Vestal Point Capital LP now owns 124,677 shares of the biotechnology company’s stock worth $1,014,000 after buying an additional 12,677 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Atara Biotherapeutics by 9.5% during the third quarter. Geode Capital Management LLC now owns 46,720 shares of the biotechnology company’s stock worth $380,000 after purchasing an additional 4,043 shares in the last quarter. FMR LLC grew its holdings in shares of Atara Biotherapeutics by 41.7% during the third quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock worth $204,000 after buying an additional 7,381 shares in the last quarter. Finally, State Street Corp lifted its stake in shares of Atara Biotherapeutics by 52.3% in the third quarter. State Street Corp now owns 22,353 shares of the biotechnology company’s stock worth $182,000 after buying an additional 7,680 shares in the last quarter. Hedge funds and other institutional investors own 70.90% of the company’s stock.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.